Novel Automated, Functionally Closed System for Rapid Immunomagnetic Negative Selection of T Cells

INTRODUCTION

- Sufficient numbers of high purity T cells are critical to enable the successful manufacturing of next generation immunotherapies (eg, CAR-T). However, the market for automated immunomagnetic cell selection devices is extremely limited
- Existing devices have limited protocols, have complex disposable kits, require multiple input parameters, and have high run-to-run variability in terms of cell recovery and purity.
- ► Here, we present a novel rapid, functionally closed, high-purity automated device for negative immunomagnetic selection of T cells directly from leukapheresis material (Fig. 1).

Fig. 1. RoboSep[™]-C Device RoboSep[™]-C

The selection process can be performed at relevant clinical scale, is extremely time efficient, utilizes a simple disposable kit, and allows for selection of untouched T cells.

METHODS

- ▶ T cells were isolated from healthy donor fresh apheresis material.
- ► The RoboSep[™]-C was used for bead labeling and subsequent immunomagnetic selection. Bead labeling was achieved using RoboSep[™]-C Human T Cell Isolation Kit, RoboSep[™]-C disposable tubing set, and phosphate buffered saline ethylenediaminetetraacetic acid.
- Three predefined protocols were consecutively evaluated with split apheresis. Protocols accommodated the following ranges: 2.5–5, 5–10, and 10–20 billion total viable nucleated cells (Fig. 2).
- ► To compare RoboSep[™]-C (negative T-cell selection) to Alternative X (automated positive T-cell selection), we performed a head-to-head comparison using the same starting material for both instruments (3 billion total viable nucleated cells) (Fig. 3, Table 1).

Acknowledgments





Elisaveta Todorova,¹ Miguel Moreta,¹ Matthew Li,¹ Brent Morse,¹ Tirtha Chakraborty,¹ Vesna Posarac²

¹Vor Biopharma Inc, Cambridge, MA, USA; ²STEMCELL Technologies, Vancouver, VC, Canada

RESULTS



Fig. 3. RoboSep[™]-C vs Alternative X: Head-to-Head Cell Viability, Recovery, and Purity Comparison

► The RoboSepTM-C run was roughly 3 times faster compared to the alternative (1 hour, 15 min vs 3.5 hours), and demonstrated the same output cell viability (93%) with a modest improvement in CD3+ T-cell purity (97.1% vs 94.2%).

Device	Input, TVNC	Output Viability, %	Recovery, CD3, %	Purity, CD3, %
Alternative X	3 B	93	72	94.2
RoboSep™-C	3 B	93	65	97.1
TVNC_total viable nucleated cell				

i vinc, total viable nucleated cel

CONCLUSION

Here we present a novel, fully automated and closed system device for large-scale negative selection of T cells. Purified cells are at high purity and present a foundation for successful generation of CAR-T therapies in an operationally timeefficient manner.

We would like to thank the research, technical operations, and lab operations groups at Vor Biopharma. Figs. 2 and 3 were generated using GraphPad Prism. PRECISIONScientia provided editorial support.





Presented at

International Society for Cell & Gene Therapy Annual Meeting, May 4–7, 2022; San Francisco, California, USA